Influx Healthtech Ltd
Incorporated in 2020, Influx Healthtech Ltd is a CDMO which deals in nutraceuticals, Ready-to-Drink (RTD) beverages, functional nutrition and pet care.[1]
- Market Cap ₹ 676 Cr.
- Current Price ₹ 292
- High / Low ₹ 315 / 161
- Stock P/E 32.9
- Book Value ₹ 43.5
- Dividend Yield 0.00 %
- ROCE 40.0 %
- ROE 30.0 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 39.1%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Working capital days have increased from 48.1 days to 83.5 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 0 | 59 | 76 | 100 | 105 | 147 | |
| 0 | 53 | 65 | 83 | 84 | 117 | |
| Operating Profit | 0 | 6 | 11 | 17 | 21 | 30 |
| OPM % | 11% | 14% | 17% | 20% | 20% | |
| 0 | 0 | 0 | 0 | 0 | 1 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 1 | 2 | 3 | 4 |
| Profit before tax | 0 | 6 | 10 | 15 | 18 | 27 |
| Tax % | 26% | 26% | 25% | 25% | 25% | |
| 0 | 4 | 7 | 11 | 13 | 21 | |
| EPS in Rs | 0.00 | 1,800.00 | 2,880.00 | 4,452.00 | 7.37 | 8.87 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 25% |
| TTM: | 40% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 42% |
| TTM: | 54% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 77% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 45% |
| 3 Years: | 39% |
| Last Year: | 30% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0.03 | 0.03 | 0.03 | 0.03 | 18 | 23 |
| Reserves | 0 | 4 | 12 | 23 | 18 | 78 |
| 0 | 1 | 1 | 0 | 0 | 0 | |
| -0 | 12 | 16 | 18 | 34 | 23 | |
| Total Liabilities | 0 | 18 | 28 | 41 | 70 | 124 |
| 0 | 3 | 6 | 14 | 19 | 28 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 3 |
| Investments | 0 | 0 | 0 | 0 | 0 | 2 |
| 0 | 15 | 22 | 27 | 52 | 90 | |
| Total Assets | 0 | 18 | 28 | 41 | 70 | 124 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 0 | 4 | 7 | 9 | 7 | 4 | |
| 0 | -3 | -5 | -8 | -9 | -25 | |
| 0 | 1 | 0 | -1 | -0 | 45 | |
| Net Cash Flow | 0 | 1 | 2 | 0 | -2 | 23 |
| Free Cash Flow | 0 | 1 | 2 | 1 | -1 | -21 |
| CFO/OP | 89% | 87% | 70% | 56% | 41% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 64 | 66 | 58 | 113 | 84 | |
| Inventory Days | 14 | 18 | 41 | 112 | 67 | |
| Days Payable | 88 | 123 | 106 | 248 | 80 | |
| Cash Conversion Cycle | -10 | -39 | -6 | -24 | 71 | |
| Working Capital Days | 2 | 1 | 15 | 46 | 83 | |
| ROCE % | 237% | 111% | 85% | 60% | 40% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Installed Capacity - Cosmetics & Ayurvedic kg per day |
|
|||
| Installed Capacity - Nutraceuticals kg per day |
||||
| Installed Capacity - Pet Supplements & Homecare kg per day |
||||
| Number of Clients count |
||||
| Number of Products (SKUs) count |
||||
| Top 10 Client Revenue Concentration % |
||||
| Capacity Utilization - Nutraceuticals % |
||||
| Number of Export Countries count |
||||
| Number of Manufacturing Units count |
||||
Extracted by Screener AI
Documents
Announcements
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
- Submitted Regulation 74(5) certificate for quarter ended June 30, 2026.
-
Updates
- Q1FY27 update: ₹10 Cr capacity expansion, 2.5x manufacturing uplift, FY27 revenue growth guided 25–30%.
-
Reply to Clarification- Financial results
- Audited FY26 results filed; consolidated format clarified for newly incorporated subsidiary Olahey Wellness.
-
Clarification - Financial Results
- Exchange has sought clarification from Influx Healthtech Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. On …
-
Disclosure under SEBI Takeover Regulations
- Promoter group held 1,70,23,464 shares as of March 31, 2026, with no new encumbrance.
Annual reports
Concalls
-
May 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Aug 2025TranscriptAI SummaryPPT
Business Overview:[1]
a) IHTL is a contract development and manufacturing organization (CDMO) specializing in nutraceuticals, cosmetics, pet care, and home care
b) The company has approx. 3,400+ products across dietary & nutritional supplements, cosmetics, ayurvedic/herbal formulations, veterinary feed supplements, and homecare solutions
c) It operates a comprehensive business model; provides end-to-end services,
spanning product development, manufacturing, and regulatory support, enabling clients to focus on core areas like formulation, discovery, and commercialization